Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos Pockets 1.4M Grant for Alzheimer s Research; Seeks Pharma Partner

NEW YORK, Feb. 12 (GenomeWeb News) - Belgian functional genomics company Galapagos Genomics has won a €1.4 million ($1.8 million) grant from a national science institute to perform research into Alzheimer's disease, the company said today.

 

Specifically, Galapagos will use the money, awarded by the Flemish Institute for the Promotion of Industrial Scientific-Technological Research, to develop an undisclosed number of disease-relevant assays based on neuronal cells.

 

The company said it intends to use these assays with its adenoviral-based target-discovery platform. Galapagos said its goal is to work with pharma partners to develop any validated drug targets.

 

Galapagos currently has ongoing R&D collaborations with BayerBoehringer Ingelheim, and Proctor & Gamble.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.